PMID: 7540426Jan 1, 1995Paper

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

European Archives of Psychiatry and Clinical Neuroscience
H J MöllerG Chouinard

Abstract

The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients. Regression analyses in the total sample and within treatment groups confirmed a strong relationship between changes in negative symptoms and the other variables studied (R2 = 0.50-0.51, p < 0.001). Only depressive symptoms did not contribute significantly to these results (p > 0.10). Path analysis showed that the greater mean change (p < 0.05) of negative symptoms with risperidone compared to haloperidol could not be fully explained by correlations with favourable effects on positive and extrapyramidal symptoms. The relationship between shift in extrapyramidal symptoms and shift in negative symptoms failed to reach statistical significance; however, there was a clear tendency in the expected direction in both treatment groups.

References

Jan 1, 1985·Schizophrenia Bulletin·W T CarpenterL D Alphs
Feb 1, 1987·The Journal of Nervous and Mental Disease·E S ProsserL E Hollister
Apr 1, 1987·Biological Psychiatry·W F HoffmanD E Casey
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H J Möller
Jan 1, 1994·Comprehensive Psychiatry·D D MillerN C Andreasen

❮ Previous
Next ❯

Citations

Jan 1, 1996·European Archives of Psychiatry and Clinical Neuroscience·H J Möller
Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·H J Möller, H Müller
Jan 12, 2012·Psychopharmacology·Philippe CorbeilEmmanuelle Pourcher
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Feb 20, 2003·European Journal of Pharmacology·Rakesh KumarBhola N Dhawan
Oct 30, 1998·Journal of Psychiatric Research·M D Jibson, R Tandon
Oct 30, 1998·Journal of Psychiatric Research·J R DeQuardo, R Tandon
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Mar 30, 2001·Schizophrenia Research·S G SirisS R Hirsch
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Sep 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·P BechA Claus
Jul 23, 2008·Schizophrenia Bulletin·George Foussias, Gary Remington
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·H J Möller
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Ibrahim TurkozCarla M Canuso
Jun 1, 2011·European Archives of Psychiatry and Clinical Neuroscience·Victor PeraltaManuel J Cuesta
May 26, 2006·Expert Opinion on Pharmacotherapy·Michael KrebsMartin Schaefer
Apr 22, 2015·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller, Pal Czobor
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Jan 1, 1998·International Journal of Psychiatry in Clinical Practice·J Fritze, B Bandelow
Jan 1, 2004·International Journal of Psychiatry in Clinical Practice·Janusz K RybakowskiUNKNOWN RISPERIDONE-INT-59 STUDY GROUP
Jan 8, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Maria Isaac, Armin Koch
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Jul 13, 2001·Journal of Psychopharmacology·S G Siris
Jul 23, 2003·Journal of Psychopharmacology·Robin A EmsleyMichael R Greenwood
Jun 14, 2016·Schizophrenia Research·André AlemanHenderikus Knegtering
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Mar 17, 2001·International Clinical Psychopharmacology·J Kane
May 5, 2000·The Cochrane Database of Systematic Reviews·E KennedyS Gilbody
Dec 10, 2014·Therapeutic Advances in Psychopharmacology·Julie Eve DesmaraisHoward C Margolese
Oct 16, 2004·Human Psychopharmacology·Rajiv Tandon
Jun 20, 2006·Human Psychopharmacology·Pinkhas SirotaEleonora Tchernichovsky
Jan 18, 2005·CNS Drugs·Monika EdlingerW Wolfgang Fleischhacker
Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
H J Möller
The British Journal of Psychiatry : the Journal of Mental Science
P BaileyJ P Macher
Journal of Psychiatric Research
William T Carpenter
The Cochrane Database of Systematic Reviews
C WhiteheadG Lewis
© 2021 Meta ULC. All rights reserved